{"name":"Heron Therapeutics","slug":"heron","ticker":"HRTX","exchange":"NASDAQ","domain":"herontx.com","description":"Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-a","hq":"San Diego, CA","founded":0,"employees":"128","ceo":"Craig Collard","sector":"Pain / Oncology Supportive Care","stockPrice":0.82,"stockChange":0.03,"stockChangePercent":3.8,"marketCap":"$154M","metrics":{"revenue":154904000,"revenueGrowth":-0.5,"grossMargin":72.6,"rdSpend":12429000,"netIncome":-20195000,"cash":46631000,"dividendYield":0,"peRatio":1.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"SUSTOL patent cliff ($44.8M at risk)","drug":"SUSTOL","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"HTX-011","genericName":"HTX-011","slug":"htx-011","indication":"Other","status":"marketed"},{"name":"SUSTOL","genericName":"SUSTOL","slug":"sustol","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"HTX-011","genericName":"HTX-011","slug":"htx-011","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SUSTOL","genericName":"SUSTOL","slug":"sustol","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Heron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Heron Therapeutics reported its fourth quarter and full year 2023 financial results, with net sales of $44.8 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-07","type":"deal","headline":"Heron Therapeutics Announces Exclusive Distribution Agreement with Hikma Pharmaceuticals","summary":"Heron Therapeutics announced an exclusive distribution agreement with Hikma Pharmaceuticals for its SUSTOL product in the United States.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"Heron Therapeutics Receives FDA Approval for SUSTOL in the Treatment of Chemotherapy-Induced Nausea and Vomiting","summary":"Heron Therapeutics received FDA approval for SUSTOL in the treatment of chemotherapy-induced nausea and vomiting.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5pNHI3NUtQdjFINHNrRDRwQ1NIZVIxNmltMDItR2RqMk12QWtkVjBUeDdVR2E0Vmw1STB2LUF0ejFQdUFzSEtKdDQxalZoZFdiWHBTNzNoRjVQRVRSWjR3LWFPUGtFNzVXdmUyc0JR?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Heron Therapeutics Inc (HRTX) - Stock Titan","headline":"If You Invested $1,000 in Heron Therapeutics Inc (HRTX)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-27","type":"earnings","source":"simplywall.st","summary":"Heron Therapeutics (HRTX) TTM Loss Of US$20.2 Million Tests Profitability Turnaround Narrative - simplywall.st","headline":"Heron Therapeutics (HRTX) TTM Loss Of US$20.2 Million Tests Profitability Turnaround Narrative","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNbVdJUnl2OC11U2lXTUJZaDR1ekVWVkJ4N0dnUFNBUGdCYlJZU1RkQTdlQk9aZkdseWtiMGw2MjZKdjVkUVktVVpfNkZ4S1hSOUNOQ3Z5UzlMR0I4Y1RBQmxKWS1CWU1XSkUzTmZTVzNIeE1UeVYxU0lxd3RVZjg2Z1poLW1VZmlNYTVWdlFoUkIwMjNMUVIyUlk1MDNtZ283djY1cm4yS2FOTTBGNUU2cERrU0xoQ1BG?oc=5","date":"2026-02-17","type":"pipeline","source":"Stock Titan","summary":"Heron Therapeutics sets Feb. 26 webcast on 2025 results, business updates - Stock Titan","headline":"Heron Therapeutics sets Feb. 26 webcast on 2025 results, business updates","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-12","type":"pipeline","source":"simplywall.st","summary":"Here's Why Heron Therapeutics (NASDAQ:HRTX) Has A Meaningful Debt Burden - simplywall.st","headline":"Here's Why Heron Therapeutics (NASDAQ:HRTX) Has A Meaningful Debt Burden","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-05","type":"pipeline","source":"simplywall.st","summary":"Market Sentiment Around Loss-Making Heron Therapeutics, Inc. (NASDAQ:HRTX) - simplywall.st","headline":"Market Sentiment Around Loss-Making Heron Therapeutics, Inc. (NASDAQ:HRTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQbXRpQWwzaGtQU05vOU0wMjdNRjNLMHVRZUJRX2RDdHVvSE4yYklLTzEzUGdwcmVsMXZuZ1JlWXRiMXBSekpMOXBLMXE5VXdYS2FVQlVHMGdGSmZVc2dOenJwTV81YmZxSzg3N1pZblh1QXJ4Rm1vVWVIVGt3enN0RTBUMk5GRWM?oc=5","date":"2025-11-04","type":"earnings","source":"Yahoo Finance","summary":"Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance","headline":"Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQTFBxb2pnT0c1OXg2LWQtY1A4UEVIaEd6NWZfd2p4eXBPZ0UtVkpQN1FxQkQzTlE0TjBPclUyUEY0aHRBem01SlYwcmpfM0Eycld0M0x6eE5ydVpQWDZDNjVqazlaZ2h3SndzVGR6bm54YUlIZWFPWlZHMWFDSm9DX2ZEVHM5VTRzT0syaWEzOFdzVWp5NElMaDVqV2dtTC1UOHJKZTFOQ0pVcUtoYkxuX2dfRGFENGZyMXZTeG5ncTVCRVBtcWowWk9hZWhFWFVNRWF6bS1OTXdKdlQ2Zmc?oc=5","date":"2025-08-08","type":"earnings","source":"PR Newswire","summary":"Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress - PR Newswire","headline":"Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNaHEyaU11YXRZbjVyS0xISWFCajBLdnJXcjFHVEtwbG9zM2swOEd0ZllQMnNqV3MtMU5wdk54clNrOGFzV19ldm1mZjUwby1feTRFT3EtM0JaeHB4TndJQm9EUHdNSGd6a3ZseG90aTBRM3VLNFhTR3FXd0lMeEx2RkRicGpJeFRmaHo2YVVBUC1JMW9mVHlFVE83ZnJRTFBwakVkLU1RUHRLTHppWmVHRWtWRnA?oc=5","date":"2025-07-21","type":"regulatory","source":"Seeking Alpha","summary":"Heron: Middling Performance From Approved Therapies With No Pipeline (NASDAQ:HRTX) - Seeking Alpha","headline":"Heron: Middling Performance From Approved Therapies With No Pipeline (NASDAQ:HRTX)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNRWFab2VJaF90MUVlbTk2TldNQ3hvUEpnc3F1UHlyVFNKbFdTVjBqdU82eVFFNW1EU1ZOMUVqM1dYQnpQbGJMU2ZlSTRhUDBTZlNYSVNCR2JkSFZZTkhDaHRmVjV4S2d2MzA2LVlCNEdlNHNwbUFLeW5oYTVkRlpWaXFVSHJ1WS02Q1NvWlgwR21pdEdoMTdLa284dHhFMTRlRHNVRnhqTm9OalA5UHpzalRpUThuMVlfODRQNm1JTUVWRFp3TmhqNmQ1UC1IMElhMk1ITGxtZW81bjM3ZzVYUjZDUkg3bFdEQ2diTGtpQjNYdjg?oc=5","date":"2025-05-06","type":"earnings","source":"PR Newswire","summary":"Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates - PR Newswire","headline":"Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxNWFBESlJIRUFMLWtNS3ZJUnlxbk12SkR5MWNTSDVHZzhfemFBanhmelQwdk1oZ0ZxTEhOamEwUVNLcXFtQ0VYODlXeXB2aktaWXd0SkZXWG9HRTQwNjN5X3JFY21NMWpQMDd6RmNIZVZ4a3RrX1pzbVplVWYwTWxZay1Xb1hlaVo2bEpXM3dQazUxMGNDOVpZbDFoYW1ZSjcxd3A0b0FBay10bmUzR0lsTVUxdVF5WUhNa29rSVUyb2pZby1ZZFpJYllDX0RMN293ellqTXE0YTFJMWN6T2VQazQtbWlkWTBia3FBekN3?oc=5","date":"2025-05-06","type":"patent","source":"PR Newswire","summary":"Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations - PR Newswire","headline":"Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5nSldCVTUwR2c0SE5aLVhqWHNoS09YQ0xraXZhRnBzR204NHhISFVpSHp5TkNfTURkM3RXZ09kMU80R1ZJSE4zYU8tZ2JNXzVJSzNULVV1N0NQaUpXZlFBY1QzdW1yVTd2ZXlraXU3TDBCTy1pN09tYw?oc=5","date":"2025-04-23","type":"deal","source":"Yahoo Finance","summary":"5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms - Yahoo Finance","headline":"5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE12M2luZ2FYSFdzX0UxeEdraDNxcklkajhEUTg2VjlWMXhZMi1EamJmMURwUTA3QXR0RjFrb29taldkRl9YZUVGbEM5MlExd2NEVWVkbkxXLWJsZw?oc=5","date":"2015-06-20","type":"pipeline","source":"MarketBeat","summary":"Heron Therapeutics (HRTX) Stock Price, News & Analysis $HRTX - MarketBeat","headline":"Heron Therapeutics (HRTX) Stock Price, News & Analysis $HRTX","sentiment":"neutral"}],"patents":[{"drugName":"SUSTOL","drugSlug":"granisetron","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":44800000}],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Merck & Co.","Eli Lilly and Company"],"therapeuticFocus":["Pain","Oncology Supportive Care"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":12429000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-20195000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":255877000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":128,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.82,"previousClose":0.79,"fiftyTwoWeekHigh":2.61,"fiftyTwoWeekLow":0.74,"fiftyTwoWeekRange":"0.74 - 2.61","fiftyDayAverage":1.07,"twoHundredDayAverage":1.35,"beta":1.42,"enterpriseValue":243888208,"forwardPE":1.6,"priceToBook":11.51,"priceToSales":0.99,"enterpriseToRevenue":1.57,"enterpriseToEbitda":-1088.79,"pegRatio":0,"ebitda":-224000,"ebitdaMargin":-0.1,"freeCashflow":-28462376,"operatingCashflow":-27591000,"totalDebt":140638000,"debtToEquity":981.2,"currentRatio":2.48,"returnOnAssets":-0.6,"returnOnEquity":0,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":3,"targetMeanPrice":4.33,"targetHighPrice":6,"targetLowPrice":3,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.8,"institutionHeldPercent":83.7,"sharesOutstanding":188537136,"floatShares":133744474,"sharesShort":36825382,"shortRatio":17.91,"shortPercentOfFloat":19.5,"epsTrailing":-0.12,"epsForward":0.51,"revenuePerShare":0.93,"bookValue":0.07,"officers":[{"age":59,"name":"Mr. Craig Alexander Collard","title":"CEO & Director"},{"age":55,"name":"Ms. Ira  Duarte","title":"Executive VP & CFO"},{"age":63,"name":"Dr. William P. Forbes Pharm. D., Pharm.D.","title":"Executive VP & Chief Development Officer"},{"age":41,"name":"Mr. Mark E. Hensley","title":"Executive VP & COO"},{"age":null,"name":"Melissa  Jarel","title":"Executive Director of Legal"},{"age":null,"name":"Mr. Ryan  Craig","title":"Vice President of Marketing"},{"age":null,"name":"Mr. John  Aiken","title":"Executive Director of People Management & Training"},{"age":59,"name":"Dr. John C. Arthur Ph.D.","title":"Senior Vice President of Manufacturing & Supply"}],"industry":"Biotechnology","irWebsite":"http://phx.corporate-ir.net/phoenix.zhtml?c=115565&p=irol-irhome","website":"https://www.herontx.com","phone":"858 251 4400"}}